Previous 10 | Next 10 |
2024-05-07 09:01:37 ET Apple ( NASDAQ: AAPL ) recently updated its capital return plan by adding a $110B to its buyback program. According to data highlighted by Mizuho, this massive buyback program is larger than 84% of the stocks that sit inside the S&P 500.... Read ...
– Non-Small Cell Lung Cancer Development Program Data to be Presented, Including the Phase 3 EVOKE-01 Study – – Updated Results from Phase 2 EDGE-Gastric Study of Fc-Silent Anti-TIGIT Domvanalimab Plus A nti-PD-1 Zimberelimab, to be Presented ...
2024-05-04 15:30:00 ET Read the full article on Seeking Alpha For further details see: Pharma R&D productivity seen improving for the first time in years - Deloitte
NORTHAMPTON, MA / ACCESSWIRE / May 3, 2024 / Gilead Sciences Forbes has listed Gilead as one of America's Best Employers for Diversity. We believe that by championing inclusion and diversity, we not only enrich our workplace but also drive groundbreaking advancements in science. "Continuing ...
2024-05-01 14:38:49 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotech stocks are full of intriguing innovators who could help pave the way for greater gains over the years ahead. Undoubtedly, it’s virtually impossible to tell exactly which pill...
2024-04-30 15:03:39 ET Summary The biotech sector has experienced significant volatility but has returned around the same as the risk-free return from the 10-Year Treasury over the past year. There are two key items that will determine the direction of small and midcap biotech sto...
2024-04-27 15:39:17 ET More on Amgen, Cullinan Oncology, etc. Amgen: I Prefer To Chase Value And Dividends Amgen: The Giant With An Impressive Pipeline Move Over Eli Lilly: Amgen Could Be The Next Obesity Wonder Stock Cullinan Therapeutics expands into autoim...
2024-04-26 10:26:09 ET More on Gilead Sciences Gilead Sciences, Inc. (GILD) Q1 2024 Earnings Call Transcript Gilead Sciences, Inc. 2024 Q1 - Results - Earnings Call Presentation Gilead Q1 Earnings Preview: Most Gains Wiped Out - Cause For Concern? Gilead has ...
– Additional Data in Pregnant Adults Who Are Virologically Suppressed Reinforce Safety and Tolerability Profile of Biktarvy in Broad Range of People With HIV – – Perinatal Guidelines Recognize Biktarvy as Alternative Regimen for Use During Pregnancy an...
2024-04-25 21:45:15 ET Image source: The Motley Fool. Gilead Sciences (NASDAQ: GILD) Q1 2024 Earnings Call Apr 25, 2024 , 4:30 p.m. ET Operator Continue reading For further details see: Gilead Sciences (GILD) Q1 2024 Earnings Call Transcript
News, Short Squeeze, Breakout and More Instantly...
– RADIAN’s Five-Year, $25 Million Extension Will Increase Support for Local Organizations and Drive Progress to Help Turn the Tide on HIV Across the Region – – RADIAN Will Expand Geographic Focus to Provide Key Populations and Communities Im...
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Chief Medical Officer Merdad Parsey, MD, PhD, will leave the company early next year. While the company works to identify a successor, Dr. Parsey will continue as Chief Medical Officer until the first quarter of 2025 and support this trans...